Abstract CT155: Trial in progress: A phase Ia/Ib, an open-label, multicenter study of ZL-1310 to evaluate the safety, tolerability, and pharmacokinetics in subjects with small cell lung cancer

耐受性 医学 药代动力学 肺癌 打开标签 肿瘤科 临床试验 药理学 内科学 不利影响
作者
Afshin Dowlati,Alexander I. Spira,Xiaodong Shen,Yinjia Fu,Yiyuan Pan,Linda Liu,Renke Zhou,Yi‐Long Wu
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:84 (7_Supplement): CT155-CT155 被引量:1
标识
DOI:10.1158/1538-7445.am2024-ct155
摘要

Abstract Background: ZL-1310, a novel antibody-drug conjugate (ADC) targeting delta-like protein 3 (DLL3) with a camptothecin derivative as its payload via a protease-cleavable linker, employs TMALIN® (Tumor Microenvironment Activable LINker-payload) ADC technology platform. DLL3, an inhibitory Notch pathway ligand and a validated target for directed therapy, is highly expressed in more than 80% of patients with small cell lung cancer (SCLC) and also has variable expression in other neuroendocrine (NE) tumors. There remains an unmet medical need for 2nd-line SCLC, as the standard of care chemotherapy has a modest response rate of ~25%. ZL-1310 is designed to minimize payload toxicity and improve anti-tumor effectiveness. Methods: This is an open-label, multiple-dose, phase 1 study of ZL-1310 administered to subjects with relapsed/refractory (r/r) metastatic SCLC who have progressed after at least one platinum-based chemotherapy regimen. The study consists of two parts: Part 1 (dose escalation) and Part 2 (dose expansion). In Part 1, the Bayesian optimal interval (BOIN) design is employed for dose escalation, while in Part 2, patients will be randomized into two cohorts with different doses of ZL-1310 to further define safety and preliminary antitumor activity. The major inclusion criteria are as follows: (1) Subjects must have histologically or cytologically confirmed metastatic or extensive-stage SCLC with no more than 3 prior regimens in the r/r setting. (2) Subjects must have at least one measurable target lesion as defined by RECIST v1.1. (3) Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. The major exclusion criteria include: (1) Prior exposure to DLL3-targeted therapy. (2) Subjects with symptomatic or uncontrolled brain metastasis requiring concurrent treatment, impaired major organ functions, active autoimmune disease, or active infections.Part 1 Dose Escalation is recruiting subjects in the US and China. Citation Format: Afshin Dowlati, Alexander Spira, Xiaodong Shen, Yinjia Fu, Yiyuan Pan, Linda Liu, Renke Zhou, Yi-Long Wu. Trial in progress: A phase Ia/Ib, an open-label, multicenter study of ZL-1310 to evaluate the safety, tolerability, and pharmacokinetics in subjects with small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr CT155.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
糊涂的踏歌完成签到,获得积分10
1秒前
2秒前
大豆发布了新的文献求助10
2秒前
风雨枫完成签到,获得积分10
2秒前
秋风的应助被意生缘采纳,获得20
3秒前
搜集达人的应助被开心德地采纳,获得10
3秒前
打打的应助被111采纳,获得10
5秒前
5秒前
6秒前
一人发布了新的文献求助10
6秒前
daomaihu发布了新的文献求助100
7秒前
8秒前
yang发布了新的文献求助10
8秒前
认真仙人掌完成签到,获得积分10
10秒前
10秒前
Brittarrr完成签到,获得积分10
10秒前
11秒前
耍酷如柏完成签到,获得积分10
11秒前
无极微光的应助被小鱼仔采纳,获得20
11秒前
ding发布了新的文献求助10
12秒前
Ava的应助被海阔天空采纳,获得10
15秒前
16秒前
Beastest完成签到,获得积分10
17秒前
17秒前
LuYuanxin完成签到,获得积分10
19秒前
香蕉觅云的应助被muderder采纳,获得10
19秒前
lili发布了新的文献求助10
20秒前
庾傀斗发布了新的文献求助10
21秒前
insane完成签到,获得积分10
22秒前
ss_hHe完成签到,获得积分10
23秒前
23秒前
脑洞疼的应助被落子无悔采纳,获得10
23秒前
23秒前
25秒前
Valerie发布了新的文献求助10
25秒前
polaris完成签到 ,获得积分10
26秒前
26秒前
阿白头发多多完成签到,获得积分10
26秒前
feiyang完成签到,获得积分10
27秒前
28秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188617
求助须知:如何正确求助?哪些是违规求助? 9576328
关于积分的说明 21846790
捐赠科研通 7786606
什么是DOI,文献DOI怎么找? 3435356
关于科研通互助平台的介绍 2559627
邀请新用户注册赠送积分活动 2482347